Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us

Markets & Finance

Robbie Stephens Boosts Human Genome


Robertson Stephens upgraded Human Genome (HGSI)to strong buy from buy.

Analyst Michael King says the upgrade was based on strong fundamentals, upcoming clinical milestones and the rights to a genomic database reverting back to the company on June 30. He expects two new partnerships in the second half and a positive

news flow through the summer. He says the company has a rich preclinical pipeline, and expects as many as three additional Investigational New Drug applications this year.

King sees the company building one of most its formidable biopharmaceutical product portfolios over the next several years and says Human Genome is one of his favorite picks for 2001. He sees a $0.64 2001 loss and a $0.66 2002 loss.


LIMITED-TIME OFFER SUBSCRIBE NOW
 
blog comments powered by Disqus